A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

被引：0
|
作者：
Martin, Peter
Bartlett, Nancy L.
Rivera, Ildefonso Ismael Rodriguez
Revuelta, Maria
Chavez, Julio C.
Reagan, John L.
Smith, Sonali M.
LaCasce, Ann S.
Zhang, Lei
Zhai, Merry
Wu, Chengqing
Leonard, John P.
Cerchietti, Leandro
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
192
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I Study of Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Hess, Brian T.
    Cerchietti, Leandro
    Hendrickson, Lindsey
    Hill, Elizabeth
    Giri, Anshu
    Salzer, Shanta
    Hogan, Sarah
    Finch, Lacey
    Klingenberg, Robin
    Hu, Fang
    Wagner-Johnston, Nina D.
    BLOOD, 2021, 138
  • [2] Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
    Martin, Peter
    Bartlett, Nancy L.
    Chavez, Julio C.
    Reagan, John L.
    Smith, Sonali M.
    LaCasce, Ann S.
    Jones, Jeffrey
    Drew, James
    Wu, Chengqing
    Mulvey, Erin
    Revuelta, Maria, V
    Cerchietti, Leandro
    Leonard, John P.
    BLOOD, 2022, 139 (08) : 1147 - 1159
  • [3] Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial
    Belada, David
    Christensen, Jacob Haaber
    Drott, Kristina
    Snauwaert, Sylvia
    Brody, Joshua
    Narkhede, Mayur
    Offner, Fritz
    Elliot, Brian
    Liu, Tracy
    Stirner, Mariana Cota
    Abbas, Aqeel
    Falchi, Lorenzo
    Clausen, Michael Roost
    BLOOD, 2021, 138
  • [4] A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma
    Hainsworth, John D.
    Arrowsmith, Edward R.
    McCleod, Michael
    Hsi, Eric D.
    Hamid, Oday
    Shi, Peipei
    Lin, Boris K.
    Fayad, Luis E.
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 216 - 218
  • [5] ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
    Nowakowski, Grzegorz S.
    Chiappella, Annalisa
    Gascoyne, Randy D.
    Scott, David W.
    Zhang, Qingyuan
    Jurczak, Wojciech
    Ozcan, Muhit
    Hong, Xiaonan
    Zhu, Jun
    Jin, Jie
    Belada, David
    Bergua, Juan Miguel
    Piazza, Francesco
    Mocikova, Heidi
    Molinari, Anna Lia
    Yoon, Dok Hyun
    Cavallo, Federica
    Tani, Monica
    Yamamoto, Kazuhito
    Izutsu, Koji
    Kato, Koji
    Czuczman, Myron
    Hersey, Sarah
    Kilcoyne, Adrian
    Russo, Jacqueline
    Hudak, Krista
    Zhang, Jingshan
    Wade, Steve
    Witzig, Thomas E.
    Vitolo, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (12) : 1317 - +
  • [6] Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy
    Smith, Stephen D.
    Till, Brian G.
    Shadman, Mazyar S.
    Lynch, Ryan C.
    Cowan, Andrew J.
    Wu, Qian W.
    Voutsinas, Jenna
    Rasmussen, Heather A.
    Blue, Katherine
    Ujjani, Chaitra S.
    Shustov, Andrei
    Cassaday, Ryan D.
    Fromm, Jonathan R.
    Gopal, Ajay K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (06) : 1119 - 1126
  • [7] Phase I Trial of Carfilzomib plus R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
    Hill, Brian T.
    Dean, Robert M.
    Jagadeesh, Deepa
    Garcia, Alex V. Mejia
    Pohlman, Brad
    Winter, Allison M.
    Krauspe, Ethan
    Collier, Patrick
    D'Andrea, Christopher
    Morrison, Ashley
    Lehmann, Sarah
    Tomlinson, Benjamin K.
    Cooper, Brenda
    de Lima, Marcos
    Ondrejka, Sarah L.
    Hsi, Eric D.
    Caimi, Paolo
    BLOOD, 2018, 132
  • [8] Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma.
    Nowakowski, Grzegorz S.
    Kalakonda, Nagesh
    Truemper, Lorenz
    Everaus, Hele
    Fustier, Pierre
    Jaeger, Jonathan
    Manzke, Oliver
    Jager, Ulrich
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Prognostic Value of High Thymidine Kinase Activity in Previously Untreated Diffuse Large B-Cell Lymphoma Treated by R-CHOP
    Suzuki, Kazuhito
    Terui, Yasuhito
    Nishimura, Noriko
    Mishima, Yuko
    Sakajiri, Sakura
    Yokoyama, Masahiro
    Tsuyama, Naoko
    Takeuchi, Kengo
    Aiba, Keisuke
    Hatake, Kiyohiko
    BLOOD, 2012, 120 (21)
  • [10] R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes
    Seymour, John F.
    Pfreundschuh, Michael
    Trneny, Marek
    Sehn, Laurie H.
    Catalano, John
    Csinady, Eva
    Moore, Nicola
    Coiffier, Bertrand
    HAEMATOLOGICA, 2014, 99 (08) : 1343 - 1349
12345